Combo Tx Active in Recurrent, Platinum-Resistant Ovarian CancerMarch 26, 2021 1:00 pm
Ixabepilone plus bevacizumab yielded responses in a third of patients.
By Ian Ingram
Combination treatment with a microtubule stabilizing agent plus bevacizumab (Avastin) proved active for patients with recurrent chemotherapy-resistant ovarian cancer, a randomized phase II trial found.
Median progression-free … Read more